Abdominal Pain News and Research

RSS
Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.
Montefiore Medical Center first to perform minimally invasive procedure on uterine fibroids

Montefiore Medical Center first to perform minimally invasive procedure on uterine fibroids

Study confirms link between GI and autism

Study confirms link between GI and autism

Autism Speaks lauds recommendations for evaluation, diagnosis, and treatment of GI in ASD children

Autism Speaks lauds recommendations for evaluation, diagnosis, and treatment of GI in ASD children

St. John's wort not effective in treating IBS

St. John's wort not effective in treating IBS

VELCADE sNDA receives FDA approval

VELCADE sNDA receives FDA approval

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Parents and physicians should lookout for common GI symptoms in ASD patients, says landmark report

Parents and physicians should lookout for common GI symptoms in ASD patients, says landmark report

ZEGERID OTC approval triggers $20M milestone payment to Santarus

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Drop in U.S. colorectal cancer deaths

Drop in U.S. colorectal cancer deaths

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

Salix Pharmaceuticals discusses proposed rifaximin NDA with the FDA

VERTICAL Phase II trial results for NHL released

VERTICAL Phase II trial results for NHL released

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.